Skip to content

Author

Li Wang

We have 3 of 20 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Network pharmacology and experimental verification reveal the mechanism of hederagenin in suppressing podocyte injury in focal segmental glomerular sclerosis.

In vivo and in vitro experiments demonstrated that HDG alleviated renal injury in ADR-induced FSGS in mice and attenuated TGF-β1-induced damage in MPC5 cells, which support HDG as a promising therapeutic candidate for FSGS treatment.

Xinyuan Tian, Rang-yue Han, Xiao-Jiao Gu et al. · 0 citations
Sep 2026

Complanatuside Ameliorates Renal Injury and Fibrosis in Chronic Kidney Disease by Inhibiting Tubular Cell Apoptosis via Activation of KLK1/BDKRB2.

It is found that CPT binds to KLK1, activates its expression, reduces PTEC apoptosis, and thereby attenuates renal fibrosis, and reveals that CPT binds to KLK1, promotes BDKRB2 expression, thereby reducing PTEC apoptosis and improving renal fibrosis.

Jing Gao, Rui-Zhi Tan, K. Deng et al. · 0 citations
Review Aug 2026

The Therapeutic Application of Epigenetic Regulation by Natural Herbal Compounds in Kidney Diseases.

Overall, this review highlights the promise of epigenetics-based therapeutic strategies using herbal active ingredients for kidney disease intervention, though further validation and optimization are needed for clinical application.

Qiu-Xiang Bai, Kang Luo, Long-hao Jia et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.